Pacira BioSciences Statistics
Total Valuation
PCRX has a market cap or net worth of $1.14 billion. The enterprise value is $1.28 billion.
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025, after market close.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PCRX has 46.30 million shares outstanding. The number of shares has decreased by -13.73% in one year.
| Current Share Class | 46.30M |
| Shares Outstanding | 46.30M |
| Shares Change (YoY) | -13.73% |
| Shares Change (QoQ) | -5.12% |
| Owned by Insiders (%) | 0.96% |
| Owned by Institutions (%) | 112.31% |
| Float | 45.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.74 |
| PS Ratio | 1.62 |
| Forward PS | 1.48 |
| PB Ratio | 1.43 |
| P/TBV Ratio | 3.33 |
| P/FCF Ratio | 7.15 |
| P/OCF Ratio | 6.49 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.47, with an EV/FCF ratio of 8.05.
| EV / Earnings | n/a |
| EV / Sales | 1.83 |
| EV / EBITDA | 7.47 |
| EV / EBIT | 14.21 |
| EV / FCF | 8.05 |
Financial Position
The company has a current ratio of 2.41, with a Debt / Equity ratio of 0.80.
| Current Ratio | 2.41 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | 3.40 |
| Debt / FCF | 3.99 |
| Interest Coverage | 5.06 |
Financial Efficiency
Return on equity (ROE) is -12.27% and return on invested capital (ROIC) is 3.88%.
| Return on Equity (ROE) | -12.27% |
| Return on Assets (ROA) | 3.56% |
| Return on Invested Capital (ROIC) | 3.88% |
| Return on Capital Employed (ROCE) | 7.10% |
| Revenue Per Employee | $889,585 |
| Profits Per Employee | -$131,300 |
| Employee Count | 790 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.08 |
Taxes
In the past 12 months, PCRX has paid $35.69 million in taxes.
| Income Tax | 35.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.07% in the last 52 weeks. The beta is 0.51, so PCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -14.07% |
| 50-Day Moving Average | 25.46 |
| 200-Day Moving Average | 21.40 |
| Relative Strength Index (RSI) | 44.56 |
| Average Volume (20 Days) | 557,500 |
Short Selling Information
The latest short interest is 5.83 million, so 12.60% of the outstanding shares have been sold short.
| Short Interest | 5.83M |
| Short Previous Month | 5.68M |
| Short % of Shares Out | 12.60% |
| Short % of Float | 12.73% |
| Short Ratio (days to cover) | 6.67 |
Income Statement
In the last 12 months, PCRX had revenue of $702.77 million and -$103.73 million in losses. Loss per share was -$2.27.
| Revenue | 702.77M |
| Gross Profit | 463.44M |
| Operating Income | 90.29M |
| Pretax Income | 100.55M |
| Net Income | -103.73M |
| EBITDA | 171.81M |
| EBIT | 90.29M |
| Loss Per Share | -$2.27 |
Full Income StatementBalance Sheet
The company has $493.63 million in cash and $636.46 million in debt, giving a net cash position of -$142.83 million or -$3.08 per share.
| Cash & Cash Equivalents | 493.63M |
| Total Debt | 636.46M |
| Net Cash | -142.83M |
| Net Cash Per Share | -$3.08 |
| Equity (Book Value) | 798.54M |
| Book Value Per Share | 17.25 |
| Working Capital | 445.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $175.75 million and capital expenditures -$16.35 million, giving a free cash flow of $159.40 million.
| Operating Cash Flow | 175.75M |
| Capital Expenditures | -16.35M |
| Free Cash Flow | 159.40M |
| FCF Per Share | $3.44 |
Full Cash Flow StatementMargins
Gross margin is 65.94%, with operating and profit margins of 12.85% and -14.76%.
| Gross Margin | 65.94% |
| Operating Margin | 12.85% |
| Pretax Margin | -9.68% |
| Profit Margin | -14.76% |
| EBITDA Margin | 24.45% |
| EBIT Margin | 12.85% |
| FCF Margin | 22.68% |
Dividends & Yields
PCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 13.73% |
| Shareholder Yield | 13.73% |
| Earnings Yield | -9.10% |
| FCF Yield | 13.98% |
Dividend DetailsAnalyst Forecast
The average price target for PCRX is $29.89, which is 21.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.89 |
| Price Target Difference | 21.41% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 7.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PCRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.55 |
| Piotroski F-Score | 6 |
